Pharmaceutical Rivalry and Leadership Shifts

This chapter explores the fierce competition between Eli Lilly and Novo Nordisk in the development of new weight loss and diabetes medications. It highlights the introduction of innovative drugs like Monjaro and ZepBound, while also addressing Novo's challenges, including disappointing trial results for their anticipated drug Cagrosima. Additionally, the chapter discusses the impact of these developments on investor confidence and leadership changes at Novo Nordisk following significant market losses.